Inositol for PCOS: Ratios, Metformin, and Fertility

Inositol, particularly its most studied form myo-inositol, has become one of the most widely used supplements for polycystic ovary syndrome, and a growing body of clinical evidence supports its role in improving insulin sensitivity, lowering androgen levels, and restoring more regular menstrual cycles. It is not a cure for PCOS, but the research paints a picture of a well-tolerated supplement that addresses several of the syndrome’s core metabolic and hormonal disruptions. The story gets more interesting when you look at which form matters, how it stacks up against pharmaceutical options, and where recent trials have challenged earlier optimism.

What Inositol Actually Does in the Ovary

Inositol is a naturally occurring sugar alcohol that your body produces and that you also get from food. Two forms matter in PCOS: myo-inositol (MI) and D-chiro-inositol (DCI). They play very different roles in the ovary. Myo-inositol acts as a second messenger for follicle-stimulating hormone (FSH), the hormone that helps follicles mature, and it also supports aromatase, the enzyme that converts androgens into estrogen.¹ D-chiro-inositol does roughly the opposite in the ovary: it promotes androgen production in the theca cells and dials down aromatase activity in granulosa cells.²

This distinction matters enormously. In PCOS, the enzyme that converts myo-inositol into D-chiro-inositol (called an epimerase) appears to be overactive in the ovaries, which drains local myo-inositol levels. The result is a myo-inositol deficiency right where it is needed most, contributing to poor egg quality and disrupted follicle development.³ Researchers have called this the “DCI paradox” because elsewhere in the body, like in insulin-responsive tissues, it is DCI that tends to be deficient in insulin-resistant individuals. But in the ovary specifically, the problem is reversed: there is too much DCI conversion and not enough MI left behind.⁴

Metabolic Benefits and Insulin Sensitivity

Insulin resistance sits at the center of PCOS for many people, driving excess androgen production and making weight management harder. Myo-inositol appears to meaningfully improve insulin sensitivity. In a prospective study of women with PCOS, supplementation led to significant drops in fasting insulin levels and a reduction in HOMA-IR, a standard measure of insulin resistance, from about 4.5 to about 2.7.⁵ That same study found significant reductions in LH levels and the LH-to-FSH ratio, both of which are characteristically elevated in PCOS.

The lipid profile improvements are worth noting too. Research has shown that myo-inositol supplementation can lower LDL cholesterol, raise HDL cholesterol, reduce BMI, and bring down blood pressure.⁶ These changes matter because PCOS carries an elevated long-term risk of cardiovascular disease, and metabolic improvements like these can shift that trajectory. Several mechanisms seem to be involved. The supplement has also been shown to alter genetic pathways related to insulin and lipid metabolism, which suggests the effects are not purely superficial.⁷

Acne, Hirsutism, and Androgen Levels

Excess androgens are behind many of the visible symptoms of PCOS, including acne and unwanted hair growth. Myo-inositol’s ability to lower testosterone and free testosterone translates into measurable improvements in these symptoms, though patience is required. In one study, testosterone, free testosterone, and insulin all dropped significantly after three months of supplementation, while clinical improvements in both acne and hirsutism became apparent after six months.⁸

A retrospective study looking at myo-inositol combined with magnesium found an even more detailed picture: DHEAS, testosterone, and free testosterone all fell significantly by three months, with further reductions at six months. Acne severity scores dropped and hirsutism scores (measured by the Ferriman-Gallwey scale) improved at both the three- and six-month marks.⁹ Keep in mind that six months is a realistic minimum timeline for visible skin and hair changes; this is consistent with how anti-androgen effects work generally, since existing hair follicles and acne lesions take time to respond even after hormone levels shift.

Getting the Ratio Right Between MI and DCI

Because myo-inositol and D-chiro-inositol do different things in different tissues, the ratio between them in a supplement matters. The most studied combination uses a 40:1 ratio of MI to DCI, which mimics the naturally occurring ratio in human blood plasma. A study of women with the most severe PCOS phenotype found that 40:1 supplementation significantly reduced HOMA-IR, total and free testosterone, and LH, while increasing sex hormone-binding globulin and estradiol.¹⁰

A recent review concluded that D-chiro-inositol alone has insufficient or contradictory evidence to recommend on its own, while myo-inositol alone shows positive results. The combination at a ratio of at least 40:1 appears to be the most effective approach, though researchers have suggested that even higher ratios like 66:1 or 100:1 may deserve further study.¹¹ The concern with too much DCI is not abstract. A dose-escalation study showed that increasing DCI supplementation progressively worsened oocyte quality and ovarian response, with significantly more immature eggs and fewer high-quality embryos at higher DCI doses.¹² If you are shopping for an inositol supplement and see one with a high proportion of DCI or a ratio significantly lower than 40:1, that is a red flag, especially if you are trying to conceive.

How Inositol Compares to Metformin

Metformin is the most commonly prescribed pharmaceutical for PCOS-related insulin resistance, so the natural question is how inositol stacks up. The answer depends on what outcome you care about most.

For menstrual cycle regularity, the two appear roughly comparable. A randomized trial found that cycle length shortened by about nine days in the myo-inositol group and about thirteen days in the metformin group, with no statistically significant difference between them.¹³ Another trial comparing the two found similar improvements in insulin sensitivity and menstrual regularity with no significant differences between treatments.¹⁴

Where metformin has a clearer edge is weight loss. The randomized trial mentioned above found that body weight dropped about six kilograms in the metformin group but did not change significantly in the myo-inositol group.¹⁵ Where myo-inositol has its own advantages is in glycemic control and lipid markers. One head-to-head trial found that myo-inositol outperformed metformin on fasting glucose, insulin levels, HOMA-IR, triglycerides, and VLDL cholesterol over twelve weeks.¹⁶

Perhaps more practically, the side effect profile is dramatically different. A meta-analysis found that women taking metformin were about five times more likely to experience adverse events, mostly gastrointestinal complaints like nausea and diarrhea, compared to those taking myo-inositol.¹⁷ For women who cannot tolerate metformin’s GI effects, this alone may be a deciding factor.

Combining Inositol and Metformin

Rather than choosing between the two, combining inositol with metformin appears to offer additional benefits. A meta-analysis of five randomized controlled trials found that the combination significantly improved menstrual cycle regularity compared to metformin alone.¹⁸ A separate trial found that women receiving the combination reported significantly greater improvements in quality of life and menstrual regularity, though hormonal and metabolic lab values did not differ significantly between the combination and metformin alone.¹⁹ One particularly interesting finding from the combination research: when metformin was paired with myo-inositol in insulin-resistant PCOS patients, TSH levels dropped significantly more than with metformin alone, suggesting a benefit for those who also have subclinical thyroid issues.²⁰

Fertility and Egg Quality

Myo-inositol’s impact on fertility is one of the main reasons it gained popularity in PCOS circles. A systematic review of randomized trials concluded that myo-inositol is capable of restoring spontaneous ovarian activity and fertility in most patients with PCOS.²¹ In women undergoing IVF, myo-inositol supplementation led to more mature follicles, more recovered eggs, better embryo quality scores, and fewer immature oocytes compared to controls.²²

That said, the evidence is not a slam dunk for every fertility endpoint. A systematic review and meta-analysis looking at clinical pregnancy rates after IVF found a trend toward improvement with myo-inositol supplementation, but the result did not reach statistical significance.²³ In plain terms, myo-inositol seems to improve the raw materials (more eggs, better quality) without yet proving it consistently raises the final pregnancy rate in IVF. Whether better egg quality translates into a baby is influenced by many factors beyond what an inositol supplement can control.

Pregnancy Outcomes and a Major Reality Check

For years, smaller trials and reviews suggested that inositol supplementation during pregnancy could reduce the risk of gestational diabetes, especially in high-risk groups like women with PCOS, obesity, or a family history of type 2 diabetes.²⁴ A meta-analysis of randomized controlled trials found that starting myo-inositol around the twelfth or thirteenth week of pregnancy reduced the risk of gestational diabetes by about 70% compared to placebo.²⁵

Then came a large, rigorous randomized controlled trial published in JAMA in 2025, and it threw cold water on this narrative. The trial gave 4 grams per day of myo-inositol or placebo to over 450 pregnant women with PCOS and found no difference whatsoever: gestational diabetes occurred in about 17% of the inositol group versus about 16% of the placebo group. The composite outcome of gestational diabetes, preeclampsia, or preterm birth was also nearly identical between groups. The authors stated plainly that myo-inositol supplementation during pregnancy did not reduce complications and should not be recommended as dietary advice for pregnant individuals with PCOS.²⁶

This is the kind of finding that reshapes a field. The earlier positive results came from smaller trials, often in mixed populations. When tested rigorously in a large cohort specifically of women with PCOS, the benefit disappeared. If you are pregnant with PCOS and considering inositol for gestational diabetes prevention, this trial should weigh heavily in your conversation with your provider.

Safety and Side Effects

Inositol’s safety profile is genuinely impressive for a supplement with this many studied indications. Clinical evidence indicates that only the highest dose studied, 12 grams per day, produced mild gastrointestinal side effects such as nausea, gas, and diarrhea, and the severity did not increase further with higher dosages.²⁷ At the standard dose used in most PCOS studies, typically 2 to 4 grams per day of myo-inositol, side effects are uncommon and generally mild.

In head-to-head comparisons with metformin, inositol consistently comes out ahead on tolerability. The risk of adverse events is roughly five times higher with metformin.²⁸ This matters for adherence: a supplement you can actually take consistently for months without GI misery is more likely to deliver real-world results than a medication you keep skipping because it upsets your stomach.

When Standard Doses Do Not Work

Some women with PCOS do not respond to standard myo-inositol supplementation, a phenomenon sometimes called “inositol resistance.” Several mechanisms may contribute to this, including genetic variations in the proteins involved in myo-inositol synthesis and transport, competitive interactions with structurally similar molecules, and individual differences in intestinal absorption and kidney handling of inositol.²⁹

One approach that has emerged for non-responders involves combining myo-inositol with alpha-lactalbumin, a whey protein that appears to help other molecules cross biological membranes more effectively. The idea is to improve the intestinal absorption of myo-inositol so that more of it actually reaches target tissues. Early evidence suggests this combination can restore ovulation in women who did not respond to myo-inositol alone.³⁰ ³¹ This research is still relatively new, but it is worth knowing about if you have tried myo-inositol for several months without seeing changes in your cycle or lab values.

Mood and Mental Health

PCOS is associated with higher rates of depression and anxiety, driven partly by hormonal disruption and partly by the psychological burden of the condition itself. One randomized, double-blind trial compared myo-inositol and metformin to placebo on mental health measures over twelve weeks. The myo-inositol group showed significantly greater improvements in depression scores, general health questionnaire scores, and combined depression-anxiety-stress scores compared to the metformin group. Interestingly, the inositol group also had a significant increase in total antioxidant capacity in the blood, suggesting that some of the mental health benefit may be linked to reduced oxidative stress.³² This is a single trial, so it would be premature to call inositol an antidepressant for PCOS. But for people already considering it for metabolic and hormonal reasons, a possible mood benefit is a welcome bonus.

Teenagers and Early Intervention

PCOS is increasingly diagnosed in adolescence, but treatment in teenagers is complicated. Metformin requires a prescription and can be hard to tolerate. Oral contraceptive pills manage symptoms but come with their own metabolic trade-offs, including potential weight gain. Myo-inositol has been studied in teenagers with PCOS and found to be a safe and effective way to prevent and correct metabolic disruptions. When combined with oral contraceptives, it enhanced the anti-androgen effects while counterbalancing the weight gain and metabolic downsides often associated with the pill.³³ For adolescent patients and their families who are wary of long-term pharmaceutical use at a young age, this is a meaningful finding.

Inflammation and Vascular Health

Beyond the hormonal and metabolic endpoints that dominate most PCOS research, there is emerging evidence that myo-inositol may have direct anti-inflammatory and antioxidant effects on blood vessels. A study of endothelial cells exposed to chronic high blood sugar found that cells from women who had taken myo-inositol showed significantly less monocyte adhesion (an early step in arterial plaque formation), lower expression of adhesion molecules on the cell surface, and reduced intracellular reactive oxygen species compared to cells from women managed by diet alone.³⁴ This is laboratory-level evidence, not a clinical outcome trial, so it does not prove that taking inositol will prevent heart disease. But given that PCOS carries elevated cardiovascular risk and that chronic low-grade inflammation is thought to be part of the mechanism, these findings open an interesting line of research. If myo-inositol turns out to protect blood vessels while simultaneously improving insulin sensitivity and hormone balance, that would make it unusually well suited for a condition that affects multiple organ systems at once.